![]() |
![]() |
![]() |
|
|
|
SHH Signaling as a Therapeutic Target in Prostate CancerFunding:Principal Investigator:Lab Website:Project Summary: The epithelial-mesenchymal interactions of prostate cancer are a promising
target for new therapies to arrest tumor growth. We have shown that hedgehog
signaling plays a critical role in initiating fetal prostate development.
This pathway is downregulated in the normal adult prostate but is re-activated
in human prostate cancer. We propose to validate hedgehog signaling as
a target for therapy in prostate cancer. During mouse fetal prostate development,
the urogenital sinus epithelium expresses Sonic hedgehog (Shh). Secreted
Shh peptide activated a transcription factor, Gli, in the surrounding
mesenchymal cells and thereby turns on the target genes activated in response
to hedgehog signaling. Blockade of hedgehog signaling prevents mesenchymal
Gli activation and abrogates prostate development. Shh and Gli are downregulated
shortly after birth and are expressed at only low levels in the adult
prostate. Shh and Gli are similarly expressed in the developing human
prostate and down-regulated in the adult. However, Shh and Gli are routinely
and coordinately re-expressed in prostate cancer. We postulated that cancer
cells commandeer hedgehog signaling to recruit stromal cells to support
tumor growth and used the LNCaP xenograft tumor model to demonstrate:
(1) that Shh expressed by LNCaP tumor cells activates Gli expression in
the tumor stroma, (2) that LNCaP Shh overexpression increases stromal
Gli expression, and (3) that Shh overexpression dramatically accelerates
tumor growth.
Referring Physicians Please Click Here First published: 6/08 Last updated:
11/24/09
webmaster@urology.wisc.edu |
||